Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00655499|
Recruitment Status : Completed
First Posted : April 10, 2008
Last Update Posted : August 23, 2012
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panitumumab together with irinotecan may kill more tumor cells.
PURPOSE: This phase II clinical trial is studying giving panitumumab together with irinotecan to see how well it works as third-line therapy in treating patients with metastatic colorectal cancer.
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Biological: panitumumab Drug: irinotecan hydrochloride Genetic: chromogenic in situ hybridization Genetic: fluorescence in situ hybridization Genetic: gene expression analysis Other: laboratory biomarker analysis||Phase 2|
- To assess the objective response rate when panitumumab is administered in combination with irinotecan hydrochloride as third-line therapy in patients with advanced metastatic colorectal cancer without KRAS mutation (wild type) previously treated with FOLFOX or XELOX chemotherapy with or without bevacizumab and irinotecan hydrochloride alone or FOLFIRI or CAPIRI chemotherapy with or without bevacizumab.
- To assess the efficacy in terms of disease control rate, duration of response, time to response, progression-free survival, time to progression, time to treatment failure, and duration of stable disease.
- To assess the efficacy and safety of this regimen, followed by panitumumab alone in patients who discontinue third-line irinotecan hydrochloride due to toxicity.
- To correlate this regimen with EGFR expression, detection of the functional genetic polymorphisms of the EGFR gene, EGFR gene amplification (FISH), EGFR activation detection, EGFR downstream protein and gene expression parameters, proteomics, and epigenetics.
OUTLINE: This is a multicenter study.
Patients receive panitumumab IV over 30-90 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Patients who discontinue irinotecan hydrochloride may receive panitumumab monotherapy. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
Archived tumor tissue specimens are obtained at baseline for correlative laboratory studies. Tissue samples are analyzed for EGFR amplification status by chromogenic in situ hybridization and fluorescence in situ hybridization, KRAS and KRAF mutations, and STAT3 expression.
After completion of study therapy, patients are followed at approximately 56 days.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||68 participants|
|Masking:||None (Open Label)|
|Official Title:||An Open-label Phase II Clinical Trial of Panitumumab in Combination With Irinotecan for Patients With Advanced Metastatic Colorectal Cancer Without KRAS Mutation (Wild Type) in Third Line Chemotherapy (Patients Pretreated With FOLFOX or XELOX ± Bevacizumab and Irinotecan Alone or FOLFIRI or CAPIRI ± Bevacizumab) [PIMABI]|
|Study Start Date :||June 2008|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
- Objective response rate (ORR; radiologically confirmed complete response [CR] or partial response [PR]) during the combination therapy phase
- ORR during the entire treatment phase (i.e., combination therapy and monotherapy)
- Disease control rate (DCR)
- Duration of response
- Time to response
- Progression-free survival time
- Time to progression
- Duration of stable disease
- Time to treatment failure
- Correlation between KRAS and KRAF mutations, EGFR gene copy number, and ORR and DCR
- Incidence and severity of adverse events
- Changes in laboratory values
- Change in vital signs
- Investigational medicinal product compliance
- Incidence of dose adjustments
- Incidence of concurrent medications
- Changes from baseline over time in WHO performance status
- Biomarkers (EGFR amplification status by chromogenic in situ hybridization and FISH, KRAS and KRAF mutations, and STAT3 expression
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00655499
|Centre Paul Papin|
|Angers, France, 49036|
|Hopital Prive Jean Mermoz|
|Lyon, France, 69008|
|Hopital Clinique Claude Bernard|
|Metz, France, 57072|
|Centre Hospitalier Intercommunal Le Raincy - Montfermeil|
|Montfermeil, France, 93370|
|Paris, France, 75013|
|Hopital Bichat - Claude Bernard|
|Paris, France, 75018|
|Hopital Saint Antoine|
|Paris, France, 75571|
|Paris, France, 75970|
|Suresnes, France, 92151|
|Principal Investigator:||Thierry Andre, MD||GERCOR - Multidisciplinary Oncology Cooperative Group|